Luspatercept as a Therapy for Myelodysplastic Syndromes with Ring Sideroblasts

Luspatercept is a promising alternative to ESAs for a subset of transfusion-dependent patients with lower risk myelodysplastic syndromes, namely those with a sideroblastic phenotype who are either not suitable for or have already failed erythropoietin-based treatment.